Key result
Pioglitazone reduced obesity-related periprostatic white adipose tissue inflammation in mice by inducing adiponectin and suppressing MCP-1 levels.
Why the study?
Does pioglitazone reduce obesity-related periprostatic white adipose tissue inflammation in mice?
Population
Obese mice, MCP-1 knockout mice, and cultured 3T3-L1 cells
Design
Preclinical
Authors
Loading...
Pioglitazone effects on periprostatic inflammation remain unproven in humans; leaves open translation of adiponectin/MCP-1 findings to cancer prevention.
Does pioglitazone reduce obesity-related periprostatic white adipose tissue inflammation in mice?
Pioglitazone attenuates obesity-related periprostatic white adipose tissue inflammation via the PPARγ–adiponectin–MCP-1 axis in preclinical models, suggesting a potential mechanism to reduce prostate cancer risk.
Miyazawa et al. (2017) studied Obesity-related periprostatic white adipose tissue inflammation. Pioglitazone was evaluated on Periprostatic WAT inflammation (density of CLS, levels of TNFα, TGFβ, MCP-1). Pioglitazone reduced obesity-related periprostatic white adipose tissue inflammation in mice by inducing adiponectin and suppressing MCP-1 levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: